A naturally occurring nucleoside analog that possesses antitumor activity, also is a potent and efficacious readthrough agent.

A natural tetranortriterpenoid compound that inhibits Hsp90 and induce the degradation of Hsp90-dependent client proteins.

A natural poduct that functions as a splicing inhibitor with IC50 of 35 uM, blocks a late stage of spliceosome assembly..

A natural furanocoumarin that is found to be a potent inhibitor of debenzylation activity of CYP3A4 enzyme with IC50 of 24.92 uM.

A nanomolar potent, selective, and orally bioavailable glycine transporter type-1 (GlyT1) inhibitor for the treatment of negative symptoms associated with schizophrenia.

A mycotoxin produced from F. moniliforme, and an inhibitor of ceramide synthase (sphingosine N-acyltransferase/CerS).

A multichannel blocker agent that has antiarrhythmic activity.

A moderately potent, but highly selective α2-adrenoceptor antagonist, the only reported selective antagonist at the α2B-adrenoceptor not having potent α1-adrenoceptor antagonist activity.

A metabolite of tamoxifen, orally active non-steroidal selective estrogen receptor modulator (SERM) for the treatment of estrogen receptor-positive breast cancer..

A metabolite of ST1535, which is potent, selective A2A adenosine receptor antagonist with Ki of 6.6 nM..

A metabolite of Gefitinib, which is a potent inhibitor of tyrosine phosporylation in EGFR..

A membrane permeable IP3 receptor antagonist and broad TRP channels (TRPC5, TRPM2) blcoker.

A melanoma-selective anticancer agent (IC50=30 nM, Malme-3M cell line), induces cell death by autophagocytosis, targeting the cancer-protective protein dermcidin.

A marine sponge alkaloid that inhibits Chk1 and Chk2 with IC50 of 3 and 3.5 uM, respectively.

A Mannich base compound, selective and orally active JAK3 inhibitor that blocks IL-2-induced activation of JAK3 and downstream substrates STAT5a/b.

A macrolide antibiotic that effectively inhibits tumor angiogenesis by suppressing VEGFR2-mediated signaling pathways in lung cancer.

A loop diuretic used to treat high blood pressure and the swelling, a novel ligand and inhibitor of MAP2K6 kinase that inhibits MAP2K6 in part through alkylation of a nonconserved cysteine residue.

A long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma.

A locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties for pain relief and anti-inflammatory treatment of inflammatory conditions.

A local anesthetic.

A linear sulfated polysaccharide extracted from red edible seaweeds, shows topical microbicide activity targeting HIV viruses.

A imidazoline compound that stimulate insulin release by inhibition of ATP-dependent K+ channels and inducing of Ca2+ mobilization in mouse pancreatic beta-cells.

A homogenous mixture of compound that is used to stain amyloid plaques, binds to amyloid fibrils but not monomers and gives a distinct increase in fluorescence emission..

A HIV-1 surface-membrane inhibitor, also is a Fap1-blocking small molecule that replicates SLV peptied functions.

A hit compound that inhibits the proliferation of human peripheral blood T cells stimulated with anti-CD3 with IC50 of <10 nM, inhibits TCR-Nck interaction..

A higly potent, orally bioavailable, BBB permeable 5-HT7 receptor antagonist with Ki of 153 pM, with slightly lesser potency toward 5-HT6, 5-HT2A and 5HT-2C (Ki = 1.2-2.0  nM).

A highly specific myosin II ATPase inhibitor.

A highly selective, small molecule inhibitor of the miRNA regulatory complex RISC subunit SND1.

A highly selective, potent, BBB penetrant and orally bioavailable 5-HT6R antagonist for the treatment of neurological disorders such as AD and schizophrenia.

A highly selective, potent, BBB penetrant and orally bioavailable 5-HT6R antagonist for the treatment of neurological disorders such as AD and schizophrenia.